{"schema_version":"secwatch.filing_event.v1","accession":"0000313143-22-000015","form_type":"8-K","ticker":"HAE","cik":"0000313143","company_name":"HAEMONETICS CORP","filed_at":"2022-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:04:09.208769+00:00","generated_at":"2026-06-26T21:31:14.798017+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Haemonetics appoints James D'Arecca as CFO effective April 11, 2022; Burke to retire","bullets":["James D'Arecca appointed CFO effective April 11, 2022; William Burke steps down as CFO on that date.","D'Arecca previously CFO at TherapeuticsMD; prior roles at Allergan, Bausch & Lomb, Merck, PwC.","Compensation: $525k base salary, 75% target bonus, $1.1M LTI target, $400k sign-on bonus.","Initial equity grant valued at $600k: 50% RSUs, 50% options, vesting 25% annually over 4 years."],"urls":{"canonical":"https://secwatch.observer/filing/0000313143-22-000015","json":"https://secwatch.observer/filing/0000313143-22-000015.json","markdown":"https://secwatch.observer/filing/0000313143-22-000015.md","text":"https://secwatch.observer/filing/0000313143-22-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/313143/000031314322000015/0000313143-22-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/313143/000031314322000015/hae-20220321.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T21:31:14.798017+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2072d06178","claim":"James C. D'Arecca was appointed as Chief Financial Officer at HAEMONETICS CORP.","evidence_excerpt":"On March 21, 2022, the Company announced the appointment of James C. D’Arecca as its Chief Financial Officer, effective April 11, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/313143/000031314322000015/0000313143-22-000015-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"e6127c607b","claim":"William P. Burke retired as Chief Financial Officer at HAEMONETICS CORP.","evidence_excerpt":"Mr. Burke will step down as Chief Financial Officer and principal financial officer of the Company on April 11, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/313143/000031314322000015/0000313143-22-000015-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}